The latest update is out from Holista Colltech Limited ( (AU:HCT) ).
Holista Colltech Ltd has initiated legal proceedings against The ProImmune Company, LLC and its director, Albert Crum, in the Supreme Court of Western Australia. The proceedings seek damages and an injunction related to alleged false representations by ProImmune that led to distribution agreements and a US judgment against Holista. This legal action has delayed the preparation of Holista’s annual accounts for 2024, which are now being lodged.
More about Holista Colltech Limited
Holista Colltech Ltd is a research-driven biotech company formed from the merger of Holista Biotech Sdn Bhd and Colltech Australia Ltd. Listed on the Australian Securities Exchange, the company is headquartered in Perth and operates in multiple countries, including Malaysia and North America. Holista focuses on developing natural solutions for healthier living, providing proprietary solutions for food manufacturers to create healthier alternatives without chemicals, and has expertise in collagen and nano-collagen technologies.
YTD Price Performance: 138.46%
Average Trading Volume: 255,599
Technical Sentiment Signal: Hold
Current Market Cap: A$8.86M
See more insights into HCT stock on TipRanks’ Stock Analysis page.